Fortenberry James D, Paden Matthew L
Critical Care Division, Children's Healthcare of Atlanta at Egleston, Atlanta, GA 30322, USA.
Semin Pediatr Infect Dis. 2006 Apr;17(2):72-9. doi: 10.1053/j.spid.2006.04.005.
Desire to restore the balance of body elements has enamored physicians since the ancient practice of bloodletting. More recently, extracorporeal techniques have been employed in both adults and children in treating sepsis. Extracorporeal therapies include continuous renal replacement (CRRT), plasma-based removal techniques, and extracorporeal membrane oxygenation (ECMO). These treatments could theoretically 1) provide immunohomeostasis of pro- and anti-inflammatory cytokines and other sepsis mediators, 2) decrease organ microthrombosis through removal of pro-coagulant factors and modulating the impaired septic coagulation response in sepsis, and 3) provide mechanical support of organ perfusion during the acute septic episode to allow time for response to traditional sepsis therapies and antimicrobials. CRRT is beneficial in managing fluid overload and acute renal failure in sepsis. Removal of sepsis mediators through the technique is variable, and the outcome impact of CRRT on sepsis has not been definitively determined. High-flow CRRT has demonstrated benefit in septic adults. Intriguing early results suggest that plasma exchange could improve outcomes in both adults and children. Based on experience, ECMO is recommended for refractory septic shock in neonates and should be considered for use in children. Ongoing trials may help determine whether the promise of extracorporeal therapies translates into outcome improvement in septic children.
自古代放血疗法以来,恢复身体元素平衡的愿望就吸引着医生。最近,体外技术已被用于成人和儿童的脓毒症治疗。体外治疗包括持续肾脏替代治疗(CRRT)、基于血浆的清除技术和体外膜肺氧合(ECMO)。从理论上讲,这些治疗可以:1)实现促炎和抗炎细胞因子及其他脓毒症介质的免疫稳态;2)通过去除促凝血因子和调节脓毒症中受损的脓毒症凝血反应来减少器官微血栓形成;3)在急性脓毒症发作期间为器官灌注提供机械支持,以便有时间对传统脓毒症治疗和抗菌药物作出反应。CRRT在管理脓毒症中的液体超负荷和急性肾衰竭方面有益。通过该技术去除脓毒症介质的效果各不相同,CRRT对脓毒症的结局影响尚未明确确定。高流量CRRT已在脓毒症成人患者中显示出益处。有趣的早期结果表明,血浆置换可能改善成人和儿童的结局。根据经验,ECMO推荐用于新生儿难治性脓毒症休克,儿童也应考虑使用。正在进行的试验可能有助于确定体外治疗的前景是否能转化为脓毒症儿童结局的改善。